Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cmic CRO Of Japan To Buy Drug-Production Plant From Daiichi Sankyo

This article was originally published in PharmAsia News

Executive Summary

Japan's Cmic plans to buy a Daiichi Sankyo manufacturing plant to produce oral and injection drug formulations. The contract research organization is expanding its business beyond conducting clinical trials to producing products for pharmaceutical companies, including Daiichi Sankyo. The acquisition of the Daiichi Sankyo Propharma plant in Japan is expected to give Cmic the capacity to produce 1.5 billion tablets and 3 million vials of drugs a year. The purchase price still has to be settled between the two firms. (Click here for more - a subscription may be required



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts